Dr. Hayes on the Future of Biomarkers for Breast Cancer

Daniel F. Hayes, MD
Published: Monday, Jun 05, 2017



Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.

It is important to determine better ways to identify which patients after 5 years of endocrine-therapy should continue it or switch to another form of therapy, explains Hayes.

According to Hayes, liquid biopsies are exciting and might have a role in determining which patients should be left on their current treatment.
 
SELECTED
LANGUAGE


Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.

It is important to determine better ways to identify which patients after 5 years of endocrine-therapy should continue it or switch to another form of therapy, explains Hayes.

According to Hayes, liquid biopsies are exciting and might have a role in determining which patients should be left on their current treatment.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x